BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38766854)

  • 1. Copy number variations in malignant melanoma: genomic regions, biomarkers, and therapeutic targets.
    Lukáčová E; Pös O; Túryová E; Hurtová T; Hanzlíková Z; Szemes T; Burjanivová T
    Neoplasma; 2024 Apr; 71(2):143-152. PubMed ID: 38766854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E2F1 germline copy number variations and melanoma susceptibility.
    Rocca MS; Benna C; Mocellin S; Rossi CR; Msaki A; Di Nisio A; Opocher G; Foresta C
    J Transl Med; 2019 May; 17(1):181. PubMed ID: 31142321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare Germline Copy Number Variations and Disease Susceptibility in Familial Melanoma.
    Shi J; Zhou W; Zhu B; Hyland PL; Bennett H; Xiao Y; Zhang X; Burke LS; Song L; Hsu CH; Yan C; Chen Q; Meerzaman D; Dagnall CL; Burdette L; Hicks B; Freedman ND; Chanock SJ; Yeager M; Tucker MA; Goldstein AM; Yang XR
    J Invest Dermatol; 2016 Dec; 136(12):2436-2443. PubMed ID: 27476724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic copy number analysis of a spectrum of blue nevi identifies recurrent aberrations of entire chromosomal arms in melanoma ex blue nevus.
    Chan MP; Andea AA; Harms PW; Durham AB; Patel RM; Wang M; Robichaud P; Fisher GJ; Johnson TM; Fullen DR
    Mod Pathol; 2016 Mar; 29(3):227-39. PubMed ID: 26743478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of copy number variations in melanocytic lesions utilising array based comparative genomic hybridisation.
    Mesbah Ardakani N; Thomas C; Robinson C; Mina K; Harvey NT; Amanuel B; Wood BA
    Pathology; 2017 Apr; 49(3):285-291. PubMed ID: 28274670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations.
    Jurmeister P; Wrede N; Hoffmann I; Vollbrecht C; Heim D; Hummel M; Wolkenstein P; Koch I; Heynol V; Schmitt WD; Thieme A; Teichmann D; Sers C; von Deimling A; Thierauf JC; von Laffert M; Klauschen F; Capper D
    J Pathol; 2022 Jan; 256(1):61-70. PubMed ID: 34564861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
    Broit N; Johansson PA; Rodgers CB; Walpole ST; Newell F; Hayward NK; Pritchard AL
    Mol Cancer Res; 2021 Jun; 19(6):991-1004. PubMed ID: 33707307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis.
    Ebbelaar CF; Jansen AML; Bloem LT; Blokx WAM
    Virchows Arch; 2021 Oct; 479(4):773-783. PubMed ID: 33851238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
    Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of rare germline copy number variation in melanoma-prone patients.
    Fidalgo F; Rodrigues TC; Silva AG; Facure L; de Sá BC; Duprat JP; Achatz MI; Rosenberg C; Carraro DM; Krepischi AC
    Future Oncol; 2016 Jun; 12(11):1345-57. PubMed ID: 27020340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POLE mutations in families predisposed to cutaneous melanoma.
    Aoude LG; Heitzer E; Johansson P; Gartside M; Wadt K; Pritchard AL; Palmer JM; Symmons J; Gerdes AM; Montgomery GW; Martin NG; Tomlinson I; Kearsey S; Hayward NK
    Fam Cancer; 2015 Dec; 14(4):621-8. PubMed ID: 26251183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach.
    Alomari AK; Miedema JR; Carter MD; Harms PW; Lowe L; Durham AB; Fullen DR; Patel RM; Hristov AC; Chan MP; Wang M; Andea AA
    Mod Pathol; 2020 Jul; 33(7):1307-1317. PubMed ID: 32066860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
    Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
    J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma.
    Hirsch D; Kemmerling R; Davis S; Camps J; Meltzer PS; Ried T; Gaiser T
    Cancer Res; 2013 Mar; 73(5):1454-60. PubMed ID: 23271725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases.
    Pfarr N; Penzel R; Klauschen F; Heim D; Brandt R; Kazdal D; Jesinghaus M; Herpel E; Schirmacher P; Warth A; Weichert W; Endris V; Stenzinger A
    Genes Chromosomes Cancer; 2016 Nov; 55(11):821-33. PubMed ID: 27218826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
    Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
    Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.
    Mordoh A; Triviño Pardo JC; Carri I; Barrio MM; Mordoh J; Aris M
    BMC Med Genomics; 2023 Jan; 16(1):1. PubMed ID: 36604730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.